75 related articles for article (PubMed ID: 10950626)
1. Perspectives on the development of new antimicrobial agents for resistant gram-positive pathogens.
Jones RN
Braz J Infect Dis; 2000 Feb; 4(1):1-8. PubMed ID: 10950626
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
3. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against streptococcus pneumoniae and enterococci isolates from the western hemisphere: example of international surveillance (SENTRY antimicrobial surveillance program )in the development of new drugs.
Lewis MT; Jones RN
Braz J Infect Dis; 2000 Feb; 4(1):15-21. PubMed ID: 10788841
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
5. Trends in antimicrobial resistance among today's bacterial pathogens.
Thornsberry C
Pharmacotherapy; 1995; 15(1 Pt 2):3S-8S. PubMed ID: 7753690
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
7. Gram-positive bacterial resistance. A challenge for the next millennium.
Bassetti M; Melica G; Cenderello G; Rosso R; Di Biagio A; Bassetti D
Panminerva Med; 2002 Sep; 44(3):179-84. PubMed ID: 12094131
[TBL] [Abstract][Full Text] [Related]
8. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
Gosbell IB; Fernandes LA; Fernandes CJ
Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
[TBL] [Abstract][Full Text] [Related]
10. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Fedler KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
[TBL] [Abstract][Full Text] [Related]
11. The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000.
McDonald LC; Lauderdale TL; Shiau YR; Chen PC; Lai JF; Wang HY; Ho M;
Int J Antimicrob Agents; 2004 Apr; 23(4):362-70. PubMed ID: 15081085
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
13. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Biedenbach DJ; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging serious Gram-positive infections.
Menichetti F
Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
16. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America).
Kirby JT; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):75-82. PubMed ID: 16876375
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
Fraise AP
J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
20. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Denys GA; Koch KM; Dowzicky MJ
Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]